🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "major milestone" in the battle against drug-resistant strains of the pathogen, according to researchers.

An International Health Concern

The sexually transmitted infection are increasing around the world, with data suggesting in excess of 82 million infections per year. Particularly high rates are observed in Africa and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. In England, cases have reached a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary development in the context of rising global incidence, the spread of superbugs and the very limited treatment choices at this time.”

Public health authorities are increasingly worried about the rise in drug-resistant strains. The World Health Organization has listed it as a "critical concern". Recent surveillance showed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Receive Approval

One new antibiotic, alternatively called a brand name, was approved by the US FDA in recent days for combating gonorrhoea. This STI can lead to serious health problems, including infertility. Researchers anticipate that specific application of this new drug will help delay the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GSK, gained clearance in concurrent days. This medication, which is employed against UTIs, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

This new treatment emerged from a innovative non-profit model for medication research. The non-profit organisation GARDP worked alongside the pharmaceutical company its industry partner to bring it to fruition.

“This approval marks a major breakthrough in the therapy of superbug gonorrhoea, which until now has been evolving faster than antibiotic development.”

Testing Results and Worldwide Availability

According to results released by a major medical journal, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This puts it on an similar efficacy with the current standard treatment, which uses a dual-drug approach. The study included hundreds of participants from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, the non-profit has the ability to license and sell the drug in many developing nations.

Medical professionals directly involved have expressed positive views. Access to a one-pill regimen like this is seen as a "revolutionary step" for public health efforts. This is viewed as crucial to reduce the burden of the illness for individuals and to halt the transmission of extremely resistant gonorrhoea around the world.